ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Nevanac® 1 mg/ml Augentropfensuspension:Novartis Pharma Schweiz AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
S01BC10 - NepafenacATC-DDD Version 2016. Source: WHO
S - Sensory Organs

A formulation approved both for use in the eye/ear is classified in S03, while formulations only licensed for use in the eye or the ear are classified in S01 and S02, respectively.

S01 - Ophthalmologicals

Most of the drugs in this group are topical preparations. Systemic preparations with clear ophthalmological indications are also classified in this group.
Small amounts of antiseptics in eye preparations do not influence the classification, e.g. benzalconium.
See also S03 - Ophthalmological and otological preparations.

DDDs have been assigned for antiglaucoma preparations only.

S01B - Antiinflammatory Agents

This group comprises all eye preparations with non-steroidal antiinflammatory agents and corticosteroids, plain and combinations. Combinations with antiinfectives are classified in S01C - Antiinflammatory agents and antiinfectives in combination.

S01BC - Antiinflammatory Agents, Non-Steroids
 
S01BC10 - Nepafenac
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home